Strategy suggests combining surrogate markers for kidney disease progression in clinical trials


Change in urinary albumin:creatinine ratio (UACR) and glomerular filtration rate (GFR) slope are markers that are individually used as surrogates of chronic kidney disease progression in clinical trials. Investigators recently developed a strategy that combines information from the treatment effects on the two to improve the prediction of treatments’ effects on patient outcomes. Their research will be presented at ASN Kidney Week 2022 November 3–November 6.

Conservative management vs. dialysis for preventing hospitalizations in patients with advanced kidney diseases

Previous article

General purpose robots should not be weaponized: An open letter to the robotics industry and our communities

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations